Market Overview

The global breast cancer diagnostics market size, valued at USD 5.05 billion in 2024, is projected to reach USD 5.47 billion in 2025 and USD 10.51 billion by 2035, representing a CAGR of 6.8% during the forecast period.

Global breast cancer market growth, 2025 to 2035

See What’s in the Full Report - Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size and Trends

The global breast cancer diagnostics market is growing rapidly, driven by the rising prevalence of breast cancer, particularly among women and strategic collaborations between market players in oncology precision medicine and AI-driven diagnostics aim to enhance early-stage breast cancer diagnosis.
In terms of type of diagnostics test, the imaging segment holds the largest share (53%) due to its ability to detect cancer with higher precision.
Based on the product type, the instrument-based products (imaging and biopsy) segment dominates the market by holding 72% share.
On the basis of regional analysis, North America accounts for 46% of the overall market share due to high prevalence, technological advancements, and government initiatives.

Key Market Statistics

Market Size in 2025: $5.47 Billion
Estimated Market Size in 2035: $10.51 Billion
CAGR (2025-2035): 6.8%
North America: Largest market in 2025
Asia Pacific: Fastest growing region

Market Introduction

Breast cancer is highly prevalence across the globe, especially among women. As per the recent report of Breast Cancer, in 2025, nearly 316,950 women will be diagnoses with breast cancer. This high prevalence of breast cancer has created a significant burden on the healthcare industry, specifically due to lack of awareness and diagnosis at late stage. In order to increase the treatment efficacy, healthcare experts believe that early stage diagnosis can be a key to improving survival rates.

Considering the early stage detection gap, several market players are encouraging the development of advanced technologies for early diagnosis with higher precision. Notably, the market players, such as Siemens Healthineers (Germany), Philips Healthcare (Netherland) and Abbott Laboratories (US) are undertaking initiatives, such as partnerships, collaborations and investments to develop AI-based breast cancer diagnostics for early detection and treatment planning.

Do You Know That NHS Is Going to Launch World’s Biggest Trial of Artificial Intelligence in Breast Cancer?
In February 2025, the Department of Health and Social Care revealed the NHS’ biggest trial of AI in breast cancer detection alongside their dedicated cancer plan to enhance diagnosis and treatment. In this trial, five different type of AI will be deployed to read about 4,62000 of the 7,000,000 mammograms. This will be done at thirty different breast cancer screening centers which will be initiated later in 2025. However, the 2,38,000 mammograms will be scanned in conventional way by radiologist and result will be compared. If the trial is successful, this will be a key milestone for early detection of breast cancer. This trial program has been funded (£11 million) by National Institute of Health and Care Research.

The consistent focus on early breast cancer detection and penetration of government organizations alongside industrial players have made breast cancer diagnostic market immensely competitive in the future.

Market Segmentation

Based on the research, we have segmented the breast cancer diagnostics into type of test, type of cancer, type of stage, type of product, application area, end user, geographical regions, and leading players.

Breast Cancer Diagnostics Market, by Type of Diagnostics Test

Imaging
Biopsy
Genomic Tests
Blood Tests
Other Tests

Breast Cancer Diagnostics Market, by Type of Cancer

Invasive Lobular Breast Cancer
Ductal Carcinoma In Situ (DCIS)
Triple-Negative Breast Cancer
Inflammatory Breast Cancer
Others

Breast Cancer Diagnostics Market, by Type of Stage

Stage I
Stage II
Stage III
Stage IV

Breast Cancer Diagnostics Market, by Type of Product

Instrument-based Products
- Imaging
- Biopsy
Platform-based Products
- Next Generation Sequencing
- Microarrays
- PCR
- Others

Breast Cancer Diagnostics Market, by Application Area

Screening
Diagnostic & Predictive
Prognostic
Research

Breast Cancer Diagnostics Market, by End User

Hospitals & Clinics
Medical Labs & Diagnostics Centers
Other End Users

Breast Cancer Diagnostics Market, by Geographical Regions

North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- New Zealand
- Rest of the Asia-Pacific
Middle East & Africa
- Egypt
- Iran
- Iraq
- Israel
- Saudi Arabia
- South Africa
- United Arab Emirates
Latin America
- Argentina
- Brazil

Pay Only for What You Need – The Best Way to Optimize

Breast Cancer Diagnostics Market Key Insights

What are the Key Breast Cancer Diagnostics Market Drivers?

The global breast cancer diagnostic tools market is propelled by the rising incidence of breast cancer globally and rising aging population who are at greater risk of having breast cancer. It is important to highlight here that the high rising risk of breast cancer and high fatality rate has necessitated the demand for advanced diagnostics solutions for early stage diagnosis. Moreover, the heightened awareness about the benefits of early diagnosis has increased the adoption of breast imaging informatics platforms and diagnostics tools.

Will Breast Cancer Diagnostics Market Remain Competitive in the Future?

The current market landscape of breast cancer diagnostics is immensely competitive, featuring the presence of well-established, tech-giants and startup companies. Notably, the market players, such as Abbott Laboratories (US), Illumina (US), and Thermo Fisher Scientific (US) are undertaking strategic initiatives, which makes this market highly competitive. For instance, in May 2025, Illumina (US) announced the expansion of clinical oncology portfolio and in-vitro diagnostic solutions to accelerate cancer diagnosis and precision oncology for patient treatment. As more market players continue to undertake initiatives in this field, we believe that the breast cancer diagnostics industry will remain competitive in the future.

What are the Latest Advances in Early Detection for Breast Cancer?

Early detection for breast cancer has become crucial factor to treat patients, underscoring the requirement for advanced diagnostics tools and technologies. Some of the latest advances in early detection for breast cancer are listed below:

How are AI and Machine Learning Transforming Accuracy and Workflow in Breast Cancer Diagnostics?

It is worth mentioning that the market players are greatly emphasizing AI-powered mammography for accurate and real-time analysis of breast cancer. These AI algorithms act as second readers to analyze vast number of datasets in real-time. It helps in identifying subtle patterns and tumors that might got skipped through conventional approach, thereby reducing the false negative and false positive scenario during breast cancer detection. In addition, the researchers are using AI-powered mammography for early breast cancer detection to analyze genetic information and role of genome in cancer progression, making it invaluable tool for designing personalized treatment.

How Next Generation Technologies Aid in Early Disease Diagnosis?

Beyond conventional imaging technologies, the increasing innovation in next-generation imaging technologies reflects the future breast cancer diagnostics market trends. The market players are encouraging the development of technologies, such as 3D tomosynthesis for breast imaging (digital breast tomosynthesis). These technologies create 3D like images of breast for the detection of dense breast tissues. This 3D imaging also helps to distinguish between potential tumor cells and normal cells, allowing more precise diagnosis of breast cancer.

In addition, the market players are emphasizing molecular breast imaging technology. This diagnostic technology utilize radioactive tracer that highlight the metabolically active cancer cells, making it an important screening tool for breast cancer diagnosis.

Your Business is Unique – Why Shouldn’t Your Report Be?

Recent Developments in Breast Cancer Diagnostics Market

In September 2025, Stratipath (Sweden) and Visiopharm (Denmark), the two global leaders in precision oncology and AI-driven cancer diagnostics entered into the strategic collaboration to enhance early stage breast cancer diagnosis. Under this partnership, prognostic Stratipath Breast (AI solution) of Stratipath’s will be integrated with Visiopharm’s advanced biomarker scoring algorithm for faster and accurate analysis.
In July 2025, SimonMed has launched two latest AI-enhanced mammogram services (Mammogram+ and Mammogram+ Heart) aiming to support early breast cancer detection and preventive care.
In June 2025, Clairity (US) received the USFDA De Novo authorization for CLAIRITY BREAST, an advanced image-based prognostic platform, which is designed to predict five-year breast cancer risk through a regular screening mammogram.
In March 2025, GE Healthcare launched Invenia™, an automated breast ultrasound (ABUS) premium. This newly launched 3D ultrasound offer innovatives features and powered by artificial intelligence for faster and accurate screening of breast cancer.

Industry Experts on Breast Cancer Diagnostics Market

Experts believe that beyond oncology precision medicine, advances in biomarkers, diagnostics tools and personalized breast cancer screening solutions will be the future focus for better treatment outcomes.

“During 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Robin Zon (ASCO President) highlighted that the efficacy of AI tool in diagnostics and decision making process has significantly increased chances of receiving targeted treatment by patients, indicating a bright future of AI tools in cancer diagnostics.”

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Which Molecular Diagnostic Tests For Breast Cancer Gain Momentum in the Future?

Based on the type of test, the global market is categorized across imaging, biopsy, genomic tests, blood tests, and other tests. According to the breast cancer diagnostics market forecast, the imaging segment hold the highest share (53%) of the market. This dominance stems from the widespread usage of imaging diagnostic technologies, such as MRI, ultrasound, and mammography for breast cancer diagnosis.
In the future, blood tests segment is anticipated to show highest CAGR during the forecast period. This can be attributed to the growing demand for minimally invasive procedures and focus on blood-based breast cancer biomarkers for the detection of breast cancer. Additionally, the increasing emphasis on liquid biopsy innovations in breast cancer diagnostics at early stage has further contributed to the highest share of this segment.

Breast Cancer Diagnostics Market by Type of Diagnostics Test, 2025

Let’s Take a Look At Front Edge Innovation in Liquid Biopsy Tests for Cancer Detection
A team of researchers at the University of Oxford developed a new liquid biopsy test that is powered by the machine learning. This test has shown promising results in detecting six different types of cancer at early stage, such as colorectal, oesophageal, pancreatic, renal, ovarian and breast.

What Type of Breast Cancer is More Prevalent in Women and Require Early Diagnosis?

This segment highlights the distribution of global market across different type of cancer, such as invasive lobular breast cancer, ductal carcinoma in situ (DCIS), triple-negative breast cancer, inflammatory breast cancer, and others. According to the breast cancer diagnostics market report, the ductal carcinoma in situ segment is dominating the market by securing maximum share. Notably, the ductal carcinoma in situ has the potential to convert into invasive ductal carcinoma. Hence, it require early diagnosis to treat at early stage and reduce the risk of death.
Owing to its invasive nature, the demand for advanced non-invasive imaging technologies in breast cancer screening remain high for ductal carcinoma in situ, contributing to the highest CAGR of this segment in the future.

Which Diagnostic Modalities Drive the Largest Market Share?

The global market is further bifurcated across different type of product, such as instrument-based products (imaging and biopsy), platform-based products (next generation sequencing, microarrays, PCR and others). According to the breast cancer diagnostics industry analysis, the instrument-based products segment is accounting for the 72% of the overall market share. This highest share stems from the expanding usage of non-invasive imaging technologies in breast cancer screening for early diagnosis.
It is worth noting that the platform-based products segment is likely to grow at the fastest CAGR during the forecast period. This lucrative growth is driven by the growing research and development of next generation platforms for early stage breast cancer diagnosis. Additionally, the availability of platforms, such as cloud-based AI radiology tools that are with multiple diagnostic modalities aid in early stage detection with higher precision. For instance,

Why Hospitals & Clinics Holds the Maximum Share of the Market?

Based on the end user, the global market is sub-divided into hospitals & clinics, medical labs & diagnostics centers, and other end users. According to our projection, the hospitals & clinics segment is accounting for over 50% share of the breast cancer diagnostics market growth. The rising burden of breast cancer patients in hospitals is likely to fuel the requirement for advanced diagnostics solutions in breast cancer diagnosis.
It is worth noting that the medical labs & diagnostics centers segment is likely to witness highest CAGR in the future. This lucrative growth is due to the growing government support and availability of reimbursement policies to manage disease diagnosis expenses are driving the demand for innovation early breast cancer diagnosis tests.

Unlock Deeper Insights – Schedule Your Personalized Workshop Today!

Regional Analysis: Which Region is Dominating the Market?

North America Dominate the Market

According to the breast cancer diagnosis market, the North America is dominating the market by holding 46% share of the market. Several factors, such as rising prevalence of breast cancer, increasing technological advanced and government initiatives to support early breast cancer diagnosis is fueling the market growth in this region.

Breast Cancer Diagnostics market share by geographical regions, 2025

Asia-Pacific Will Grow at a Higher CAGR

In Asia-Pacific, the market for breast cancer diagnostics is likely to grow at a higher CAGR. The high incidence of breast cancer, advancements in breast cancer diagnostic technologies and government initiatives to strengthen research and development activities in breast cancer is likely to drive the market growth in this region.

Breast Cancer Diagnostics Market: Report Deliverables

Report Deliverables	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 5.47 Billion
Market Size 2035	USD 10.51 Billion
CAGR (Till 2035)	6.8%
Segments Covered	Type of Diagnostics Test Type of Cancer Type of Stage Type of Product Application Area Geographical Regions
Key Breast Cancer Diagnostics Companies Profiled	Agilent Technologies (US) Abbott Laboratories (US) BD (US) Bio-Rad Laboratories (US) Fujifilm (Japan) GE Healthcare (US) Hitachi Medical Systems (Japan) Hologic (US) Illumina (US) Myriad Genetics (US) Natera (US) PerkinElmer (US) Philips Healthcare (Netherland) Qiagen (Germany) Roche Diagnostics (Switzerland) Siemens Healthineers (Germany) Thermo Fisher Scientific (US) (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

What are the Main Regulatory or Guideline Updates Impacting Breast Cancer Diagnostic Adoption?

Several regulatory guidelines that are impacting breast cancer diagnostic adoption are listed below:

The USFDA Breast Density Reporting Mandate: This significant change in the regulatory guidelines in the US has mandate that all the mammography and breast cancer diagnostics facilities are required to inform patients for their breast density status in their mammogram reports. This new update is expected to drive the adoption of breast cancer diagnostic technologies, such as molecular breast imaging (MBI), contrast-enhanced mammography (CEM), and ultrasound.
USPSTF Recommendations: The U.S. Preventive Services Task Force (USPSTF) has recently updated its breast cancer screening recommendations for enhance the adoption of breast cancer diagnostics. This update is now advocating for biennial mammography for women aged 40-74. This represents a shift from previous guidelines and expands the age range for routine screening, particularly for women in their early 40s.
The USFDA Breakthrough Device Designation: The USFDA has granted Breakthrough Device Designation to several AI-based tools in 2025, such as for a companion diagnostic. This designation is intended to expedite the development and review of devices that provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. This signals the FDA's willingness to support and fast-track innovative AI solutions that can improve diagnostic accuracy in oncology.

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Introduction

2.4.2.2. Types

2.4.2.2.1. Qualitative

2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques

2.4.2.4.1. Interviews

2.4.2.4.2. Surveys

2.4.2.4.3. Focus Groups

2.4.2.4.4. Observational Research

2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders

2.4.2.5.1. Company Executives (CXOs)

2.4.2.5.2. Board of Directors

2.4.2.5.3. Company Presidents and Vice Presidents

2.4.2.5.4. Key Opinion Leaders

2.4.2.5.5. Research and Development Heads

2.4.2.5.6. Technical Experts

2.4.2.5.7. Subject Matter Experts

2.4.2.5.8. Scientists

2.4.2.5.9. Doctors and Other Healthcare Providers

2.4.2.6. Ethics and Integrity

2.4.2.6.1. Research Ethics

2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

+ 3. MARKET DYNAMICS

3.1. Forecast Methodology

3.1.1. Top-Down Approach

3.1.2. Bottom-Up Approach

3.1.3. Hybrid Approach

3.2. Market Assessment Framework

3.2.1. Total Addressable Market (TAM)

3.2.2. Serviceable Addressable Market (SAM)

3.2.3. Serviceable Obtainable Market (SOM)

3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques

3.3.1. Qualitative Forecasting

3.3.2. Correlation

3.3.3. Regression

3.3.4. Time Series Analysis

3.3.5. Extrapolation

3.3.6. Convergence

3.3.7. Forecast Error Analysis

3.3.8. Data Visualization

3.3.9. Scenario Planning

3.3.10. Sensitivity Analysis

3.4. Key Considerations

3.4.1. Demographics

3.4.2. Market Access

3.4.3. Reimbursement Scenarios

3.4.4. Industry Consolidation

3.5. Robust Quality Control

3.6. Key Market Segmentations

3.7. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Overview of Major Currencies Affecting the Market

4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact

4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt

4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Overview of Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product (GDP)

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. R&D Innovation

4.2.11.7. Stock Market Performance

4.2.11.8. Supply Chain

4.2.11.9. Cross-Border Dynamics

+ 5. EXECUTIVE SUMMARY

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Overview of Breast Cancer Diagnostics

6.2.1. Role of Breast Cancer Diagnostics

6.2.2. Advantages of Breast Cancer Diagnostics

6.2.3. Challenges Associated with Breast Cancer Diagnostics

6.3. Future Perspective

+ 7. REGULATORY SCENARIO

+ 8. COMPREHENSIVE DATABASE OF LEADING PLAYERS

+ 9. COMPETITIVE LANDSCAPE

9.1. Chapter Overview

9.2. Breast Cancer Diagnostics: Overall Market Landscape

9.2.1. Analysis by Year of Establishment

9.2.2. Analysis by Company Size

9.2.3. Analysis by Location of Headquarters

9.2.4. Breast Cancer Diagnostics: Overall Market Landscape

9.2.4.1. Analysis by Test Type

9.2.4.2. Analysis by Cancer Area

9.2.4.3. Analysis by Stage Type

9.2.4.4. Analysis by Product Type

9.2.4.5. Analysis by Application Type

9.2.4.6. Analysis by END USER

+ 10. COMPETITIVE COMPETITIVENESS ANALYSIS

+ 11. STARTUP ECOSYSTEM IN THE BREAST CANCER DIAGNOSTICS MARKET

11.1. Breast Cancer Diagnostics: Market Landscape of Startups

11.1.1. Analysis by Year of Establishment

11.1.2. Analysis by Company Size

11.1.3. Analysis by Company Size and Year of Establishment

11.1.4. Analysis by Location of Headquarters

11.1.5. Analysis by Company Size and Location of Headquarters

11.1.6. Analysis by Ownership Structure

11.2. Key Findings

+ 12. COMPANY PROFILES

12.1. Chapter Overview

12.2. Agilent Technologies (US)

12.2.1. Company Overview

12.2.2. Company Mission

12.2.3. Company Footprint

12.2.4. Management Team

12.2.5. Contact Details

12.2.6. Financial Performance

12.2.7. Operating Business Segments

12.2.8. Product Portfolio

12.2.9. MOAT Analysis

12.2.10. Recent Developments and Future Outlook

* similar detail is presented for other below mentioned companies based on information in the public domain

12.3. Abbott Laboratories (US)

12.4. BD (US)

12.5. Bio-Rad Laboratories (US)

12.6. Fujifilm (Japan)

12.7. GE Healthcare (US)

12.8. Hitachi Medical Systems (Japan)

12.9. Hologic (US)

12.10. Illumina (US)

12.11. Myriad Genetics (US)

12.12. Natera (US)

12.13. PerkinElmer (US)

12.14. Philips Healthcare (Netherland)

12.15. Qiagen (Germany)

12.16. Roche Diagnostics (Switzerland)

12.17. Siemens Healthineers (Germany)

12.18. Thermo Fisher Scientific (US)

+ 13. PORTER'S FIVE FORCES ANALYSIS

+ 14. PATENT ANALYSIS

14.1. Chapter Overview

14.2. Scope and Methodology

14.3. Breast Cancer Diagnostics: Patent Analysis

14.3.1. Analysis by Patent Publication Year

14.3.2. Analysis by Type of Patent and Patent Publication Year

14.3.3. Analysis by Patent Application Year

14.3.4. Analysis by Patent Jurisdiction

14.3.5. Analysis by CPC Symbols

14.3.6. Analysis by Type of Applicant

14.3.7. Leading Industry Players: Analysis by Number of Patents

14.3.8. Leading Individual Assignees: Analysis by Number of Patents

+ 15. PARTNERSHIPS AND COLLABORATIONS

15.1. Chapter Overview

15.2. Partnership Models

15.3. Breast Cancer Diagnostics: Partnerships and Collaborations

15.3.1. Analysis by Year of Partnership

15.3.2. Analysis by Type of Partnership

15.3.3. Analysis by Year and Type of Partnership

15.3.4. Analysis by Type of Partner

15.3.5. Analysis by Location of Headquarters of Partner

15.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner

15.3.7. Most Active Players: Analysis by Number of Partnerships

15.3.8. Regional Analysis

15.3.8.1. Intercontinental and Intracontinental Deals

15.3.8.2. Local and International Deals

+ 16. GRANT ANALYSIS

16.1. Chapter Overview

16.2. Scope and Methodology

16.3. Breast Cancer Diagnostics: Grant Analysis

16.3.1. Analysis by Year of Grant Award

16.3.2. Analysis by Amount Awarded

16.3.3. Analysis by Support Period

16.3.4. Analysis by Support Period and Funding Institute Center

16.3.5. Analysis by Type of Grant Application

16.3.6. Analysis by Purpose of Grant Award

16.3.7. Analysis By Activity Code

16.3.8. Analysis by NIH Spending Category

16.3.9. Analysis by Study Section Involved

16.3.10. Popular NIH Departments: Analysis by Number of Grants

16.3.11. Analysis by Type of Recipient Organization

16.3.12. Prominent Program Officers: Analysis by Number of Grants

16.3.13. Popular Recipient Organizations: Analysis by Number of Grants

16.3.14. Popular Recipient Organizations: Analysis by Grant Amount

16.3.15. Analysis by Region of Recipient Organizations

+ 17. FUNDING AND INVESTMENTS ANALYSIS

17.1. Funding Models

17.2. Breast Cancer Diagnostics: Funding and Investments

17.2.1. Analysis by Year of Funding

17.2.2. Analysis of Funding Instances by Type of Funding

17.2.3. Analysis of Funding Instances by Year and Type of Funding

17.2.4. Analysis of Amount Invested by Type of Funding

17.2.5. Analysis of Funding Instances by Country

17.2.6. Most Active Players: Analysis by Amount Raised

17.3. Summary and Key Takeaways

+ 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET

18.1. Chapter Overview

18.2. Key Assumptions and Methodology

18.3. Trends Disruption Impacting Market

18.4. Demand Side Trends

18.5. Supply Side Trends

18.6. Global Breast Cancer Diagnostics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

18.7. Multivariate Scenario Analysis

18.7.1. Conservative Scenario

18.7.2. Optimistic Scenario

18.8. Investment Feasibility Index

18.9. Key Market Segmentations

+ 19. MARKET OPPORTUNITIES BASED ON TYPE OF DIAGNOSTICS TEST

19.1. Chapter Overview

19.2. Key Assumptions and Methodology

19.3. Revenue Shift Analysis

19.4. Market Movement Analysis

19.5. Penetration-Growth (P-G) Matrix

19.6. Breast Cancer Diagnostics Market for Imaging: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.7. Breast Cancer Diagnostics Market for Biopsy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.8. Breast Cancer Diagnostics Market for Genomic Tests: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.9. Breast Cancer Diagnostics Market for Blood Tests: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.10. Data Triangulation and Validation

19.10.1. Secondary Sources

19.10.2. Primary Sources

19.10.3. Statistical Modeling

+ 20. MARKET OPPORTUNITIES BASED ON TYPE OF CANCER

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Revenue Shift Analysis

20.4. Market Movement Analysis

20.5. Penetration-Growth (P-G) Matrix

20.6. Breast Cancer Diagnostics Market for Invasive Lobular Breast Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.7. Breast Cancer Diagnostics Market for Ductal Carcinoma In Situ (DCIS): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.8. Breast Cancer Diagnostics Market for Triple-Negative Breast Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.9. Breast Cancer Diagnostics Market for Inflammatory Breast Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.10. Breast Cancer Diagnostics Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.11. Data Triangulation and Validation

20.11.1. Secondary Sources

20.11.2. Primary Sources

20.11.3. Statistical Modeling

+ 21. MARKET OPPORTUNITIES BASED ON TYPE OF STAGE

21.1. Chapter Overview

21.2. Key Assumptions and Methodology

21.3. Revenue Shift Analysis

21.4. Market Movement Analysis

21.5. Penetration-Growth (P-G) Matrix

21.6. Breast Cancer Diagnostics Market for Stage I: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.7. Breast Cancer Diagnostics Market for Stage II: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.8. Breast Cancer Diagnostics Market for Stage III: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.9. Breast Cancer Diagnostics Market for Stage IV: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.10. Data Triangulation and Validation

21.10.1. Secondary Sources

21.10.2. Primary Sources

21.10.3. Statistical Modeling

+ 22. MARKET OPPORTUNITIES BASED ON TYPE OF PRODUCT

22.1. Chapter Overview

22.2. Key Assumptions and Methodology

22.3. Revenue Shift Analysis

22.4. Market Movement Analysis

22.5. Penetration-Growth (P-G) Matrix

22.6. Breast Cancer Diagnostics Market for Instrument-Based Products: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.6.1. Breast Cancer Diagnostics Market for Imaging: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.6.2. Breast Cancer Diagnostics Market for Biopsy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7. Breast Cancer Diagnostics Market for Platform-Based Products: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7.1. Breast Cancer Diagnostics Market for Next Generation Sequencing: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7.2. Breast Cancer Diagnostics Market for Microarrays: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7.3. Breast Cancer Diagnostics Market for PCR: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7.4. Breast Cancer Diagnostics Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.8. Data Triangulation and Validation

22.8.1. Secondary Sources

22.8.2. Primary Sources

22.8.3. Statistical Modeling

+ 23. MARKET OPPORTUNITIES BASED ON APPLICATION AREA

23.1. Chapter Overview

23.2. Key Assumptions and Methodology

23.3. Revenue Shift Analysis

23.4. Market Movement Analysis

23.5. Penetration-Growth (P-G) Matrix

23.6. Breast Cancer Diagnostics Market for Screening: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.7. Breast Cancer Diagnostics Market for Diagnostic & Predictive: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.8. Breast Cancer Diagnostics Market for Prognostic: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.9. Breast Cancer Diagnostics Market for Pharmaceutical and Biotechnology Companies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.10. Breast Cancer Diagnostics Market for Research: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.11. Data Triangulation and Validation

23.11.1. Secondary Sources

23.11.2. Primary Sources

23.11.3. Statistical Modeling

+ 24. MARKET OPPORTUNITIES BASED ON END USER

24.1. Chapter Overview

24.2. Key Assumptions and Methodology

24.3. Revenue Shift Analysis

24.4. Market Movement Analysis

24.5. Penetration-Growth (P-G) Matrix

24.6. Breast Cancer Diagnostics Market for Hospitals & Clinics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.7. Breast Cancer Diagnostics Market for Medical Labs & Diagnostics Centers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.8. Breast Cancer Diagnostics Market for Other End Users: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.9. Data Triangulation and Validation

24.9.1. Secondary Sources

24.9.2. Primary Sources

24.9.3. Statistical Modeling

+ 25. MARKET OPPORTUNITIES FOR BREAST CANCER DIAGNOTICS IN NORTH AMERICA

25.1. Chapter Overview

25.2. Key Assumptions and Methodology

25.3. Revenue Shift Analysis

25.4. Market Movement Analysis

25.5. Penetration-Growth (P-G) Matrix

25.6. Breast Cancer Diagnostics Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.1. Breast Cancer Diagnostics Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.2. Breast Cancer Diagnostics Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.6.3. Breast Cancer Diagnostics Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.7. Data Triangulation and Validation

+ 26. MARKET OPPORTUNITIES FOR BREAST CANCER DIAGNOTICS IN EUROPE

26.1. Chapter Overview

26.2. Key Assumptions and Methodology

26.3. Revenue Shift Analysis

26.4. Market Movement Analysis

26.5. Penetration-Growth (P-G) Matrix

26.6. Breast Cancer Diagnostics Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.1. Breast Cancer Diagnostics Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.2. Breast Cancer Diagnostics Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.3. Breast Cancer Diagnostics Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.4. Breast Cancer Diagnostics Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.5. Breast Cancer Diagnostics Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.6.6. Breast Cancer Diagnostics Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.7. Data Triangulation and Validation

+ 27. MARKET OPPORTUNITIES FOR BREAST CANCER DIAGNOTICS IN ASIA-PACIFIC

27.1. Chapter Overview

27.2. Key Assumptions and Methodology

27.3. Revenue Shift Analysis

27.4. Market Movement Analysis

27.5. Penetration-Growth (P-G) Matrix

27.6. Breast Cancer Diagnostics Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.1. Breast Cancer Diagnostics Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.2. Breast Cancer Diagnostics Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.3. Breast Cancer Diagnostics Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.4. Breast Cancer Diagnostics Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.5. Breast Cancer Diagnostics Market in New Zealand: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.6.6. Breast Cancer Diagnostics Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.7. Data Triangulation and Validation

+ 28. MARKET OPPORTUNITIES FOR BREAST CANCER DIAGNOTICS IN MIDDLE EAST AND AFRICA (MEA)

28.1. Chapter Overview

28.2. Key Assumptions and Methodology

28.3. Revenue Shift Analysis

28.4. Market Movement Analysis

28.5. Penetration-Growth (P-G) Matrix

28.6. Breast Cancer Diagnostics Market in Middle East and Africa (MEA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.1. Breast Cancer Diagnostics Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.2. Breast Cancer Diagnostics Market in Iran: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.3. Breast Cancer Diagnostics Market in Iraq: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.4. Breast Cancer Diagnostics Market in Israel: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.5. Breast Cancer Diagnostics Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.6. Breast Cancer Diagnostics Market in South Africa: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.7. Breast Cancer Diagnostics Market in United Arab Emirates: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.7. Data Triangulation and Validation

+ 29. MARKET OPPORTUNITIES FOR BREAST CANCER DIAGNOTICS IN LATIN AMERICA

29.1. Chapter Overview

29.2. Key Assumptions and Methodology

29.3. Revenue Shift Analysis

29.4. Market Movement Analysis

29.5. Penetration-Growth (P-G) Matrix

29.6. Breast Cancer Diagnostics Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6.1. Breast Cancer Diagnostics Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6.2. Breast Cancer Diagnostics Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.7. Data Triangulation and Validation

+ 30. KEY WINNING STRATEGIES

+ 31. SWOT ANALYSIS

+ 32. ROOTS STRATEGIC RECOMMENDATIONS

+ 33. INSIGHTS FROM PRIMARY RESEARCH

+ 34. REPORT CONCLUSION

+ 35. TABULATED DATA

+ 36. LIST OF COMPANIES AND ORGANIZATIONS

+ 37. CUSTOMIZATION OPPORTUNITIES

+ 38. ROOTS SUBSCRIPTION SERVICES

+ 39. AUTHOR DETAILS

Breast Cancer Diagnostics Market